Skip to main content
Premium Trial:

Request an Annual Quote

Lynx, on Notice from Nasdaq, Plans to Appeal Delisting

NEW YORK, Dec. 19-Lynx Therapeutics said yesterday that it has received a notice of delisting from Nasdaq, which it plans to appeal.

 

The company's stock has traded below $1.00 since July 31, meaning that it no longer complies with the Nasdaq listing maintenance standards.

 

Lynx said in a statement that it will request a hearing from the stock market, and is considering a reverse stock split or transferring its stocks to the Nasdaq SmallCap Market, which has more lenient policies.

The Scan

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.

Analysis of Endogenous Parvoviral Elements Found Within Animal Genomes

Researchers at PLOS Biology have examined the coevolution of endogenous parvoviral elements and animal genomes to gain insight into using the viruses as gene therapy vectors.

Saliva Testing Can Reveal Mosaic CNVs Important in Intellectual Disability

An Australian team has compared the yield of chromosomal microarray testing of both blood and saliva samples for syndromic intellectual disability in the European Journal of Human Genetics.

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.